<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01384058</url>
  </required_header>
  <id_info>
    <org_study_id>442006</org_study_id>
    <secondary_id>2006-005906-30</secondary_id>
    <nct_id>NCT01384058</nct_id>
  </id_info>
  <brief_title>Effect of Ezetimibe or Simvastatin or Both on Low Densitiy Lipoprotein -Subfractions in Patients With Type 2 Diabetes</brief_title>
  <acronym>EZE</acronym>
  <official_title>The Effect of Ezetimibe 10 mg, Simvastatin 20 mg and the Combination of Simvastatin 20 mg Plus 10 mg Ezetimibe on Low Density Lipoprotein (LDL)-Subfractions in Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Freiburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Essex Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Freiburg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is of interest how ezetimibe alone or in combination with statin may influence atherogenic
      dense Low Density Lipoprotein (dLDL) in patients with type 2 diabetes mellitus. The primary
      objective of this study will be whether there is a change of the concentrations of
      Apolipoprotein B (ApoB) in dLDL from baseline in each of the 3 treatment groups.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The selective cholesterol resorption inhibitor ezetimibe belongs to a new class of
      cholesterol lowering drugs. It is of interest how ezetimibe alone or in combination with
      statin may influence atherogenic dense Low Density Lipoprotein (dLDL) in patients with type 2
      diabetes mellitus.

      The primary objective of this study will be whether there is a change of the concentrations
      of Apolipoprotein B (ApoB) in dLDL from baseline in each of the 3 treatment groups. The
      comparison between treatment groups is exploratory due to insufficient power to detect any
      change between treatments.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of the concentration of apolipoprotein B (ApoB) in dense Low Densitiy Lipoprotein (dLDL) from baseline with ezetimibe, simvastatin or the combination of both drugs</measure>
    <time_frame>baseline and 6 weeks</time_frame>
    <description>multicentre, randomized, open-label study investigation in 6-week effect of ezetimibe (10mg/d), simvastatin (20mg/d) or combination of ezetimibe 10mg/simvastatin 20mg/d on concentrations of dLDL separated by preparative gradient ultracentrifugation in patients with type 2 diabetes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of the concentrations of Total Cholesterol</measure>
    <time_frame>baseline and 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the concentrations of Low Densitiy Lipoprotein (LDL) -Cholesterol</measure>
    <time_frame>baseline and 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the concentrations of High Density Lipoprotein (HDL) -Cholesterol</measure>
    <time_frame>baseline and 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the concentrations of triglycerides</measure>
    <time_frame>baseline and 6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Diabetes Mellitus Type 2</condition>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Ezetimibe 10mg/d</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intake of ezetimibe 10mg per day for six weeks after wash-out</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Simvastatin 20 mg per day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intake of simvastatin 20 mg per day for six weeks after wash-out</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ezetimibe 10 mg/d and Simvastatin 20mg/d</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intake of ezetimibe 10 mg and simvastatin 20 mg per day for six weeks after wash-out</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ezetimibe</intervention_name>
    <description>ezetimibe 10 mg per day for six weeks</description>
    <arm_group_label>Ezetimibe 10mg/d</arm_group_label>
    <other_name>Ezetrol 10 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>simvastatin</intervention_name>
    <description>Simvastatin 20 mg per day for six weeks</description>
    <arm_group_label>Simvastatin 20 mg per day</arm_group_label>
    <other_name>Zocor MSD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe 10/Simvastatin 20</intervention_name>
    <description>Ezetimibe 10mg/Simvastatin 20mg per day for six weeks</description>
    <arm_group_label>Ezetimibe 10 mg/d and Simvastatin 20mg/d</arm_group_label>
    <other_name>Inegy 10/20</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  men &gt; 18 and ≤ 75 years

          -  post-menopausal women ≤ 75 years (follicle stimulating hormone (FSH) &gt;30 mIU/ml, women
             &gt; 60 years FSH &gt; 20 mIU/ml )

          -  well controlled diabetes mellitus type II (glycohaemoglobin ≤ 8,0 %)

          -  LDL-cholesterol ≤ 160 mg/dl

          -  LDL-subfractions: concentration of apoB-100 in dLDL (LDL-5 und LDL-6) &gt; 25 mg/dl

          -  written informed consent

        Exclusion Criteria:

          -  participation in a clinical trial within the last 30 d before screening- visit

          -  patient is unable to give written informed consent

          -  Body mass index &lt;15 kg/m² and &gt; 35 kg/m²

          -  clinical atherosclerotic disease (coronary heart disease, peripheral artery disease,
             carotid artery disease)

          -  malignoma

          -  uncontrolled arterial hypertension (&gt;160/&gt;100 mmHg)

          -  clinically relevant disease of liver and/or kidneys

          -  clinically relevant endocrinally or hematologic problems

          -  allergy to study medication (Ezetimibe and/or Simvastatin)

          -  alcohol- or drug abuse

          -  laboratory: alanine aminotransferase, aspartate aminotransferase, total bilirubin &gt; 3
             x ULN, creatine kinase &gt; 5 x ULN

          -  Concurrent treatment with potent CYP3A4-inhibitors (e.g. itraconazole, ketoconazole,
             HIV-protease-inhibitors, erythromycin, clarithromycin, telithromycin und nefazodone)

          -  other relevant diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karl Winkler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Freiburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut für Stoffwechselforschung</name>
      <address>
        <city>Frankfurt</city>
        <zip>60322</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stephan Jacob, MD</name>
      <address>
        <city>Villingen-.Schwenningen</city>
        <zip>78048</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998 Jul 23;339(4):229-34.</citation>
    <PMID>9673301</PMID>
  </reference>
  <reference>
    <citation>Reaven GM, Chen YD, Jeppesen J, Maheux P, Krauss RM. Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. J Clin Invest. 1993 Jul;92(1):141-6.</citation>
    <PMID>8325978</PMID>
  </reference>
  <reference>
    <citation>Austin MA, Edwards KL. Small, dense low density lipoproteins, the insulin resistance syndrome and noninsulin-dependent diabetes. Curr Opin Lipidol. 1996 Jun;7(3):167-71. Review.</citation>
    <PMID>8818515</PMID>
  </reference>
  <reference>
    <citation>Winkler K, Abletshauser C, Hoffmann MM, Friedrich I, Baumstark MW, Wieland H, März W. Effect of fluvastatin slow-release on low density lipoprotein (LDL) subfractions in patients with type 2 diabetes mellitus: baseline LDL profile determines specific mode of action. J Clin Endocrinol Metab. 2002 Dec;87(12):5485-90.</citation>
    <PMID>12466341</PMID>
  </reference>
  <reference>
    <citation>Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation. 1990 Aug;82(2):495-506.</citation>
    <PMID>2372896</PMID>
  </reference>
  <reference>
    <citation>Nigon F, Lesnik P, Rouis M, Chapman MJ. Discrete subspecies of human low density lipoproteins are heterogeneous in their interaction with the cellular LDL receptor. J Lipid Res. 1991 Nov;32(11):1741-53.</citation>
    <PMID>1770294</PMID>
  </reference>
  <reference>
    <citation>Dejager S, Bruckert E, Chapman MJ. Dense low density lipoprotein subspecies with diminished oxidative resistance predominate in combined hyperlipidemia. J Lipid Res. 1993 Feb;34(2):295-308.</citation>
    <PMID>8429263</PMID>
  </reference>
  <reference>
    <citation>Anber V, Griffin BA, McConnell M, Packard CJ, Shepherd J. Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans. Atherosclerosis. 1996 Aug 2;124(2):261-71.</citation>
    <PMID>8830938</PMID>
  </reference>
  <reference>
    <citation>Nordestgaard BG, Nielsen LB. Atherosclerosis and arterial influx of lipoproteins. Curr Opin Lipidol. 1994 Aug;5(4):252-7. Review.</citation>
    <PMID>7981955</PMID>
  </reference>
  <reference>
    <citation>Griffin BA, Freeman DJ, Tait GW, Thomson J, Caslake MJ, Packard CJ, Shepherd J. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis. 1994 Apr;106(2):241-53.</citation>
    <PMID>8060384</PMID>
  </reference>
  <reference>
    <citation>Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA. 1996 Sep 18;276(11):875-81.</citation>
    <PMID>8782636</PMID>
  </reference>
  <reference>
    <citation>Stampfer MJ, Krauss RM, Ma J, Blanche PJ, Holl LG, Sacks FM, Hennekens CH. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA. 1996 Sep 18;276(11):882-8.</citation>
    <PMID>8782637</PMID>
  </reference>
  <reference>
    <citation>Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, Després JP. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study. Circulation. 1997 Jan 7;95(1):69-75.</citation>
    <PMID>8994419</PMID>
  </reference>
  <reference>
    <citation>Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res. 2002 Sep;43(9):1363-79. Review.</citation>
    <PMID>12235168</PMID>
  </reference>
  <reference>
    <citation>Blake GJ, Otvos JD, Rifai N, Ridker PM. Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation. 2002 Oct 8;106(15):1930-7.</citation>
    <PMID>12370215</PMID>
  </reference>
  <reference>
    <citation>ALTSCHUL R, HOFFER A, STEPHEN JD. Influence of nicotinic acid on serum cholesterol in man. Arch Biochem Biophys. 1955 Feb;54(2):558-9.</citation>
    <PMID>14350806</PMID>
  </reference>
  <reference>
    <citation>Charman RC, Matthews LB, Braeuler C. Nicotinic acid in the treatment of hypercholesterolemia. A long term study. Angiology. 1972 Jan;23(1):29-35.</citation>
    <PMID>5009984</PMID>
  </reference>
  <reference>
    <citation>DiPalma JR, Thayer WS. Use of niacin as a drug. Annu Rev Nutr. 1991;11:169-87. Review.</citation>
    <PMID>1832551</PMID>
  </reference>
  <reference>
    <citation>Winkler K, Weltzien P, Friedrich I, Schmitz H, Nickell HH, Hauck P, Hoffmann MM, Baumstark MW, Wieland H, März W. Qualitative effect of fenofibrate and quantitative effect of atorvastatin on LDL profile in combined hyperlipidemia with dense LDL. Exp Clin Endocrinol Diabetes. 2004 May;112(5):241-7.</citation>
    <PMID>15146369</PMID>
  </reference>
  <reference>
    <citation>Winkler K, Friedrich I, Baumstark MW, Wieland H, März W 2002 Pioglitazone reduces atherogenic dense low density lipoprotein (LDL) particles in patients with type 2 diabetes mellitus. Br J Diabetes Vasc Dis 2:143-148</citation>
  </reference>
  <reference>
    <citation>Winkler K, Konrad T, Füllert S, Friedrich I, Destani R, Baumstark MW, Krebs K, Wieland H, März W. Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. Diabetes Care. 2003 Sep;26(9):2588-94.</citation>
    <PMID>12941723</PMID>
  </reference>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2011</study_first_submitted>
  <study_first_submitted_qc>June 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2011</study_first_posted>
  <last_update_submitted>June 18, 2012</last_update_submitted>
  <last_update_submitted_qc>June 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Freiburg</investigator_affiliation>
    <investigator_full_name>Karl Winkler</investigator_full_name>
    <investigator_title>MD, Prof. Dr. med., Kommissarischer Ärztlicher Direktor</investigator_title>
  </responsible_party>
  <keyword>atherogenic lipoprotein</keyword>
  <keyword>cardiovascular disease</keyword>
  <keyword>coronary artery disease</keyword>
  <keyword>type 2 diabetes</keyword>
  <keyword>small, dense LDL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

